The first event of CarboHyde Cyclodextrin Masterclass I is open for registration!
About the event: Cyclodextrins in small molecule drug delivery – current trends and future directions
December 5, 2024, 8:00 am – 8:45 am (PST) / 5:00 pm – 5:45 pm (CET)
Online
You can register here with this form
Our webinar, titled “Cyclodextrins in small molecule drug delivery – current trends and future directions” is the first episode in a series of webinars (CarboHyde’s Cyclodextrin Masterclass) that aims to provide educative content to cyclodextrin users and researcher on various applications.
Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from current mainstream applications towards future trends. Our esteemed speaker will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.
Agenda:
Cyclodextrins in small molecule drug delivery – current trends and future directions
Speaker: Dr. Tamas Sohajda (CarboHyde)
Tamas will unveil the universe cyclodextrin-based drugs for all kinds of administration routes, how they are made and what is the main purpose of their use. From solubility enhancement to stability studies, discover how cyclodextrins bridge the gap between lab experiments and clinical applications. Then we will take a glimpse into the future and explore what novel formulations may offer beyond mainstream uses.
Who Should Attend: Researchers, clinicians, pharmaceutical professionals, and anyone curious about the journey of cyclodextrins—from lab discoveries to patient impact.
Don’t miss this opportunity to explore the bridge between science and healing. Register now and be part of the cyclodextrin revolution!
About the presenter:
Tamás Sohajda, CEO at Carbohyde
Tamás Sohajda started working on cyclodextrins in 2006, joined CycloLab in 2011 where he become head of quality control, later director of research and development and finally CEO.
His R&D interests are in designing new industrially important CD derivatives ideal as next generation excipients, drug delivery systems or as biologically active compounds.
He was a member of EDQM’s carbohydrate working group for 6 years, contributed to numerous research papers and international grants and is the inventor of several patents.
Currently, Tamás serves as the CEO of CarboHyde, a pharmaceutical start-up company developing cyclodextrin-based novel therapeutics.
About CarboHyde:
CarboHyde – Revolution of Cyclodextrins
CarboHyde is a private preclinical pharma company redefining industries through the unparalleled potential of cyclodextrins.
We are a group of passionate cyclodextrins-lovers who realize that there is a need for targeted industrial experience in advancing and broadening innovative projects. The company has a solid pipeline of some moonshot applications, including gene therapy and biotechnology, yet it also supports other companies and groups who seek cyclodextrin expertise.
The company fosters several preclinical programs in various neurodegenerative and rare disease indications, superior ways of delivering oligonucleotides, and various applications related to vaccines while continuously working on exploring novel applications as well.
Learn more about CarboHyde here.